CD8A and neoplasm: Using poly-ICLC and/or resiquimond as an adjuvant, a trial found that a human anti-DEC-205 monoclonal antibody fused with the tumor antigen NY-ESO-1 produced a humoral and NY-ESO-1-specific CD4 and CD8 cells response, leading to partial clinical responses without toxicity [72].